Becaplermin (Regranex) for diabetic foot ulcers

American Family Physician

Volumn 78, Issue 2, 2008, Pages 255-256

  Jarvis, Courtney I ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECAPLERMIN; PLACEBO;

ADJUVANT THERAPY; CELLULITIS; DIABETIC FOOT; DIABETIC PATIENT; DRUG ABSORPTION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; GRANULATION TISSUE; HUMAN; INFECTION; NEOPLASM; OSTEOMYELITIS; SHORT SURVEY; TREATMENT DURATION; ULCER HEALING;

EID: 67549083188     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (6)

1. Regranex (becaplermin) gel 0.01% [prescribing information]. Raritan, N.J.: Ortho-McNeil Pharmaceutical, Inc.; 2005. http://www.regranex.com/content/ backgrounders/www.regranex.com/www.regranex.com/PI-Full-Version.pdf. Accessed May 14, 2008.
2. Smiell JM. Clinical safety of becaplermin (rhPDGF-BB) gel. Becaplermin Studies Group. Am J Surg. 1998;176(2A suppl):68S-73S.
3. FDA announces new labeling changes for Regranex [news release]. Rockville, Md.: U.S. Food and Drug Administration; June 6, 2008. http://www.fda.gov/bbs/topics/NEWS/2008/NEW01845.html. Accessed June 10, 2008.
4. Wieman TJ, Smiell JM, SuY. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care. 1998;21(5):822-827.
5. Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J Vasc Surg 1995;21(1):71-81.
6. Rees RS, Robson MC, Smiell JM, Perry BH. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study. Wound Repair Regen. 1999;7(3):141-147. (Pubitemid 29331917)